Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411833 | 0.90 | SMN1; SMN2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL14059104 | 0.90 | SMN1; SMN2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL2113302 | 0.90 | SMN1; SMN2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL2986951 | 0.89 | SMYD2 (0.38) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL2479942 | 0.88 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTTTDP1 | |
| SCHEMBL31738087 | 0.87 | SMYD2 (0.35) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL25387362 | 0.86 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL14248300 | 0.86 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL1942988 | 0.86 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT | |
| SCHEMBL19331649 | 0.86 | SMYD2 (0.37) | SMYD2SMN1; SMN2CYP3A4HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739694-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | Blossomhill Therapeutics, Inc. (US) | 2026-05-13 | — | — | EP | disclosed |
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | Bugworks Research, Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| WO-2025202022-A9 | ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025202022-A1 | ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 | BAYER AKTIENGESELLSCHAFT (DE) | 2025-10-02 | — | — | WO | disclosed |
| CN-120192324-A | Heterocyclic compound, pharmaceutical composition and application | 上海医药集团股份有限公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-3548484-B1 | BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2025-04-30 | — | — | EP | disclosed |
| WO-2025076523-A1 | RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS, INC. (US) | 2025-04-10 | — | — | WO | disclosed |
| CN-119562952-A | KIF18A inhibitors | 山东轩竹医药科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119330976-A | Camptothecine compound, antibody drug conjugate, and preparation methods and application thereof | 上海医药集团股份有限公司 | 2025-01-21 | — | — | CN | disclosed |
| WO-2025010294-A2 | MACROCYCLIC COMPOUNDS AND USE AS TYK2 INHIBITORS | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | disclosed |
| EP-0980366-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-0993300-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6350892-B1 | ENZYME INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-26 | — | — | US | disclosed |
| US-6284756-B1 | ANTICOAGULANT | ELI LILLY AND COMPANY | 2001-09-04 | — | — | US | disclosed |
| US-6271227-B1 | ANTICOAGULANTS | ELI LILLY AND COMPANY | 2001-08-07 | — | — | US | disclosed |
| EP-0980366-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2000-05-17 | — | — | EP | disclosed |
| EP-0993300-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-04-19 | — | — | EP | disclosed |
| EP-0980366-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998048798-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| WO-1998049160-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577247-B2 | Diaminopyrazolo[1,5-a]pyrimidine-6-carbonitrile compounds as adenosine 2A receptor and adenosine 2B receptor antagonist | ADORA1, ADORA3, ADORA2A | SMYD2 4720/4885SMN1; SMN2 4360/4885CYP3A4 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.